Lizoforce IV Injection contains Linezolid 600 mg, a synthetic antibiotic belonging to the oxazolidinone class, indicated for the treatment of serious Gram-positive bacterial infections. It is primarily used in cases where oral administration is not feasible or when rapid therapeutic levels are required, such as in hospital-acquired pneumonia, complicated skin and soft tissue infections, and infections caused by multidrug-resistant organisms including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Linezolid exerts its antibacterial effect by inhibiting bacterial protein synthesis through binding to the 23S ribosomal RNA of the 50S subunit, thereby preventing the formation of the initiation complex essential for bacterial translation. Lizoforce IV Injection is administered intravenously, allowing for controlled and effective delivery of the drug, ensuring optimal plasma concentrations. The dosage and duration of therapy should be determined based on the severity of infection, renal function, and clinical response. Caution is advised in patients with a history of myelosuppression, serotonin syndrome risk, or peripheral neuropathy. Monitoring of blood counts is recommended during prolonged therapy. Adverse effects may include thrombocytopenia, anemia, headache, and gastrointestinal disturbances. Lizoforce IV Injection should be used under strict medical supervision to ensure efficacy and minimize potential risks.